Sitemap > Breaking Research > Oncology
Displaying 1 - 50 of 14430 results
- Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients.
- Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase.
- Inhibitor of p42/44 mitogen-activated protein kinase, but not p38 MAPK, attenuated antigen challenge of guinea pig airways in vitro.
- Preparation of novel aza-1,7-annulated indoles and their conversion to potent indolocarbazole kinase inhibitors.
- Analogs of sub-nanomolar hMC1R agonist LK-184 [Ph(CH2)3CO-His-D-Phe-Arg-Trp-NH2]. An additional binding site within the human melanocortin receptor 1?
- Aptamer selection for the inhibition of cell adhesion with fibronectin as target.
- Synthesis of potent taxoids for tumor-specific delivery using monoclonal antibodies.
- Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer.
- Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.
- Excess risk of cancer in patients with primary venous thromboembolism: a national, population-based cohort study.
- Vardenafil (Levitra) for erectile dysfunction: a systematic review and meta-analysis of clinical trial reports.
- Inhibition of papilloma progression by antisense oligonucleotides targeted to HPV11 E6/E7 RNA.
- Protection against doxorubicin cardiomyopathy in rats: role of phosphodiesterase inhibitors type 4.
- Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists.
- Differences in gene expression between B-cell chronic lymphocytic leukemia and normal B cells: a meta-analysis of three microarray studies.
- Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt.
- BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo.
- Discovery and characterization of novel small molecule inhibitors of human Cdc25B dual specificity phosphatase.
- Antitumor efficacy and tumor-selective replication with a single intravenous injection of OAS403, an oncolytic adenovirus dependent on two prevalent alterations in human cancer.
- Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors.
- Adenovirus-mediated transfer of siRNA against survivin induced apoptosis and attenuated tumor cell growth in vitro and in vivo.
- Fungal polysaccharopeptide inhibits tumor angiogenesis and tumor growth in mice.
- Noninvasive delivery of small inhibitory RNA and other reagents to pulmonary alveoli in mice.
- A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma.
- Jak kinase activity is required for lymphoma invasion and metastasis.
- SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells.
- Targeting autocrine and paracrine VEGF receptor pathways inhibits human lymphoma xenografts in vivo.
- Multistep process through which adenoviral vector vaccine overcomes anergy to tumor-associated antigens.
- Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis.
- N2-substituted O6-cyclohexylmethylguanine derivatives: potent inhibitors of cyclin-dependent kinases 1 and 2.
- Synthesis and antitumor activity of quinonoid derivatives of cannabinoids.
- Discovery of 2-(4-pyridin-2-ylpiperazin-1-ylmethyl)-1H-benzimidazole (ABT-724), a dopaminergic agent with a novel mode of action for the potential treatment of erectile dysfunction.
- Synthesis and biological evaluation of a new class of geldanamycin derivatives as potent inhibitors of Hsp90.
- Prevalence of irritable bowel syndrome: a community survey.
- The A3 adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition.
- Angiogenesis inhibition by an oncolytic herpes virus expressing interleukin 12.
- Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis.
- Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model.
- Antisense protein kinase A RIalpha inhibits 7,12-dimethylbenz(a)anthracene-induction of mammary cancer: blockade at the initial phase of carcinogenesis.
- Blockade of allergic airway inflammation following systemic treatment with a B7-dendritic cell (PD-L2) cross-linking human antibody.
- Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia.
- Possible (enzymatic) routes and biological sites for metabolic reduction of BNP7787, a new protector against cisplatin-induced side-effects.
- Is interleukin-13 critical in maintaining airway hyperresponsiveness in allergen-challenged mice?
- Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration.
- Comparison of selective retinoic acid receptor- and retinoic X receptor-mediated efficacy, tolerance, and survival in cutaneous t-cell lymphoma.
- Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
- Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts.
- Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.
- A QSAR study on inhibitory activities of 1-phenylbenzimidazoles against the platelet-derived growth factor receptor.
- Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 | 65 | 66 | 67 | 68 | 69 | 70 | 71 | 72 | 73 | 74 | 75 | 76 | 77 | 78 | 79 | 80 | 81 | 82 | 83 | 84 | 85 | 86 | 87 | 88 | 89 | 90 | 91 | 92 | 93 | 94 | 95 | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | 117 | 118 | 119 | 120 | 121 | 122 | 123 | 124 | 125 | 126 | 127 | 128 | 129 | 130 | 131 | 132 | 133 | 134 | 135 | 136 | 137 | 138 | 139 | 140 | 141 | 142 | 143 | 144 | 145 | 146 | 147 | 148 | 149 | 150 | 151 | 152 | 153 | 154 | 155 | 156 | 157 | 158 | 159 | 160 | 161 | 162 | 163 | 164 | 165 | 166 | 167 | 168 | 169 | 170 | 171 | 172 | 173 | 174 | 175 | 176 | 177 | 178 | 179 | 180 | 181 | 182 | 183 | 184 | 185 | 186 | 187 | 188 | 189 | 190 | 191 | 192 | 193 | 194 | 195 | 196 | 197 | 198 | 199 | 200 | 201 | 202 | 203 | 204 | 205 | 206 | 207 | 208 | 209 | 210 | 211 | 212 | 213 | 214 | 215 | 216 | 217 | 218 | 219 | 220 | 221 | 222 | 223 | 224 | 225 | 226 | 227 | 228 | 229 | 230 | 231 | 232 | 233 | 234 | 235 | 236 | 237 | 238 | 239 | 240 | 241 | 242 | 243 | 244 | 245 | 246 | 247 | 248 | 249 | 250 | 251 | 252 | 253 | 254 | 255 | 256 | 257 | 258 | 259 | 260 | 261 | 262 | 263 | 264 | 265 | 266 | 267 | 268 | 269 | 270 | 271 | 272 | 273 | 274 | 275 | 276 | 277 | 278 | 279 | 280 | 281 | 282 | 283 | 284 | 285 | 286 | 287 | 288 | 289 Next >